Paper Details

  1. Home
  2. Paper Details

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.

Author: BerenguerJuan, CaoHuyen, GallantJoel, LiuYa-Pei, MoyleGraeme, MyersJoel, RosenblattLisa, ShalitPeter, SzwarcbergJavier, YangLingfeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Cobicistat and ritonavir are medications used to enhance the effectiveness of other antiretroviral drugs. This study compared the efficacy and safety of atazanavir combined with either cobicistat or ritonavir in HIV-infected adults.
Paper Details　
Original Abstract of the Article :
Cobicistat (COBI) enhances atazanavir (ATV) pharmacokinetic parameters similarly to ritonavir (RTV) in both healthy volunteers and HIV-infected adults. Primary efficacy and safety outcomes of this Phase 3, international, randomized, double-blind, double-dummy, active- controlled trial in HIV-1-infec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543662/

データ提供：米国国立医学図書館（NLM）

Atazanavir Plus Cobicistat: A New Era in HIV Treatment

The fight against HIV/AIDS, like a desert journey with many challenges, requires constant innovation and development of effective treatments. This study explores the efficacy and safety of atazanavir (ATV) combined with cobicistat (COBI) as a treatment for HIV-1 infection. The researchers, like a caravan navigating a challenging route, aim to assess the effectiveness of this new drug combination in comparison to existing therapies.

The study found that ATV+COBI was non-inferior to ATV combined with ritonavir (RTV) in terms of virologic suppression and safety. The results suggest that ATV+COBI offers a viable alternative treatment option for HIV-1 infection, with comparable effectiveness and safety to established therapies.

Expanding Treatment Options for HIV-1 Infection

This study highlights the importance of exploring new treatment options for HIV-1 infection and offers a promising alternative to existing regimens. The findings showcase the potential of ATV+COBI to provide effective and well-tolerated treatment for individuals living with HIV.

A Step Forward in the Fight Against HIV

This study's findings contribute to the growing arsenal of effective HIV treatments and offer hope for individuals seeking safe and effective management of this complex condition. It demonstrates the ongoing progress in the field of HIV research and highlights the potential for continued innovation in developing new treatment strategies.

Dr.Camel's Conclusion

The development of new HIV treatments, like a series of oases along a challenging desert journey, provides hope for individuals living with this complex condition. This study's findings suggest that ATV+COBI offers a promising new option for effective and well-tolerated HIV treatment.

Date :
  1. Date Completed 2018-03-19
  2. Date Revised 2018-12-20
Further Info :

Pubmed ID

27774892

DOI: Digital Object Identifier

PMC5543662

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.